ADELIS Technologies

Greetings to our esteemed Japanese partner KINRYO ELECTRIC for presenting our #ZETALIF Induced Fluorescence Detector at #JASIS2024. #Fluorescence #DNA

Discover our BIABooster Innovative Solution for DNA analysis in oncology, on our partner’s booth ID SOLUTIONS (Hall 3 – Booth #653). This multi-injection platform enables analysis of the size profile of cell-free DNA directly from plasma at very high sensitivity <5 fg/µL. #DNA #RNA #oncology #ESMO2024

We are pleased to inform that Prof. Sebastien Salas (AP-HM, Cancer Research Center of Marseille) will be presenting a poster on SChISM study at ESMO 2024 Barcelona. This clinical study using BIABooster innovative technology is aimed to assess the performance of the cfDNA size profile before treatment to early predict response and survival following immunotherapy for four cancer types, to early adapt therapeutic strategy and prevent ICI-related progression or toxicity. Come and discuss with him on : ”Long circulating-free DNA fragments predict early-progression (EP) and progression-free-survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): a new biomarker”. #cfDNA #Biomarker #immunotherapy

CE PHARM 2024: Join Frédéric Ginot on Monday 16th September for a presentation on practical implementations of DNA analysis by electro-hydrodynamic actuation, focusing on examples where no prior purification of DNA is required. View the abstract: https://lnkd.in/eUjbxruP https://lnkd.in/dNVAFrq2 #CEPharm2024 #Adelis #DNA #RNA

ASCO 2024: ADELIS participates in groundbreaking study predicting Immunotherapy resistance with cell-free DNA analysis Our findings highlight that cell-free DNA fragments can predict early progression in patients with advanced or metastatic cancer undergoing immune-checkpoint inhibition. Standard PD-L1 testing identifies 60% of newly diagnosed patients as eligible for immuno-oncology treatments. However, 20% of eligible patients are missed, and among those identified, 50% do not respond to treatment, with about 30% experiencing severe adverse effects. The SCHISM study, presented at ASCO 2024, is addressing this critical issue by analyzing circulating DNA fragments. Intermediate data from this groundbreaking study were showcased at the conference. A key factor in the project's success is the size profile analysis of circulating DNA, enabled by our BIABOOSTER technology. Read the full abstract online: https://vist.ly/3beyd #DNA #Oncology #Sequencing

Congratulations to Valérie Taly, Stéphanie Descroix, and Karla Perez-Toralla on the publication of "Microfluidics Diagnostics, Methods, and Protocols" in the esteemed Methods in Molecular Biology series. We are proud to have contributed to Chapter 2, which details the efficient measurement of circulating DNA size distribution using microfluidic chips and capillary electrophoresis instruments. Learn more: https://vist.ly/38ph8 #DNA #sequencing #biology

Meet Frédéric Ginot, Chief Technlogy Officer of ADELIS Frédéric brings an impressive dual background in instrument engineering and biology to ADELIS. A graduate of the prestigious École Polytechnique (Paris, France, 1985) and holder of a PhD in Molecular Biology (University Paris VII, 1989), he boasts 29 years of experience in the biology and biotechnology sector. Throughout his career, Frédéric has led numerous development teams on industrial projects, consistently bridging the gap between engineering and biosciences. His expertise spans across various fields, including medical devices (Hemodia), in vitro diagnostics (BioMérieux, CEA-LETI), and molecular biology (Genethon, Bertin Technologies). "I’m proud of what we’ve accomplished to convert an academic invention to a turn-key product with outstanding analytical performances for nucleic acids analysis. It was a hard and multidisciplinary route, full of good and bad surprises and encounters, always guided by a strong will of delivering an excellent and useful analytical system to biologists." Feel free to connect with Frédéric in the comments below.

Revolutionize your analysis with the ability to see what nobody has seen before! Our innovative multi-injection technology unlocks the potential to analyze ultra-low concentration samples. This means you can use minimal quantities and save your precious samples, while still achieving groundbreaking results. Key benefits: - Analyze previously undetectable samples - Minimize sample usage - Maximize efficiency and cost savings Experience the future of analysis with Adelis' patented Multi-Injection technology. Learn more: https://vist.ly/3ayhu #DNA #sequencing #fragmentation

Meet Jean-Charles Garcia, Chief Operating Officer of ADELIS Jean-Charles Garcia is the founder and COO of ADELIS, bringing over 30 years of experience in developing products and introducing new technologies to the market. His expertise spans a wide range of industries, with a particular focus on complex and innovative analytical equipment and methods. Jean-Charles earned his engineering degree from INSA Toulouse in 1985, followed by a PhD in physics from CNRS, Sophia Antipolis in 1988. Throughout his career, he has played a key role in creating and shaping six companies specializing in industrial instrumentation, telecommunications, and software. With his extensive background and entrepreneurial spirit, Jean-Charles continues to drive ADELIS towards excellence and innovation in analytical instrumentation. #TechLeader #EntrepreneurialSpirit #INSAalumni